CPH 82.
CPH 82 [Reumacon] is a purified semi-synthetic lignan glycoside derivative of the medicinal herb Podophyllum emodi which inhibits microtubules. It has been jointly developed by the Swedish company Conpharm and the Swiss company Analytecon SA. It has potential for the treatment of rheumatoid arthritis. The Swedish company Meda is licencing the drug and has taken over responsibility from Conpharm for development and documentation. Meda has obtained exclusive marketing rights for Reumacon worldwide, except in China and some other Asian countries. Meda plans to form partnerships with other companies in the marketing of Reumacon.
D000284:Administration, Oral; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006027:Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D017705:Lignans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017239:Paclitaxel; D011034:Podophyllotoxin
C059428:CPH 82; D006027:Glycosides; D017705:Lignans; D011034:Podophyllotoxin; D017239:Paclitaxel